AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Update

Share on StockTwits

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 21,735,300 shares, a growth of 6.5% from the May 30th total of 20,409,600 shares. Based on an average daily trading volume, of 3,260,000 shares, the days-to-cover ratio is presently 6.7 days. Approximately 21.6% of the shares of the stock are sold short.

A number of large investors have recently modified their holdings of AVEO. Rhumbline Advisers grew its holdings in AVEO Pharmaceuticals by 50.4% during the 4th quarter. Rhumbline Advisers now owns 138,271 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 46,307 shares during the last quarter. New York State Common Retirement Fund grew its holdings in AVEO Pharmaceuticals by 261.3% during the 4th quarter. New York State Common Retirement Fund now owns 248,600 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 179,800 shares during the last quarter. BlackRock Inc. grew its holdings in AVEO Pharmaceuticals by 3.3% during the 4th quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after purchasing an additional 236,822 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in AVEO Pharmaceuticals by 28.0% during the 4th quarter. Bank of New York Mellon Corp now owns 423,673 shares of the biopharmaceutical company’s stock valued at $678,000 after purchasing an additional 92,663 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in AVEO Pharmaceuticals by 3.0% during the 4th quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock valued at $1,882,000 after purchasing an additional 34,164 shares during the last quarter. Institutional investors own 28.33% of the company’s stock.

Several analysts have recently issued reports on the stock. National Securities restated a “sell” rating and set a $5.00 target price on shares of Oxford Square Capital in a research report on Thursday, March 28th. Zacks Investment Research cut shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. AVEO Pharmaceuticals presently has an average rating of “Hold” and an average price target of $1.96.

Shares of NASDAQ:AVEO opened at $0.74 on Wednesday. AVEO Pharmaceuticals has a 12 month low of $0.49 and a 12 month high of $3.59. The firm’s 50-day moving average price is $0.72.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.74 million. AVEO Pharmaceuticals had a net margin of 70.30% and a negative return on equity of 24.50%. On average, equities analysts predict that AVEO Pharmaceuticals will post -0.17 earnings per share for the current fiscal year.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

See Also: What are municipal bonds?

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.